



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:
- 1, 5-9, 28-31, 126-128, 130-132, 134 (all completely), 50, 51
61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 135
136 (all partially)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1, 5-9, 28-31, 126-128, 130-132, 134 (all completely),
50, 51, 61-64, 67-70, 73, 76-87, 90-92,
98-105, 110-112, 115-118,
135, 136 (all partially)

A peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags; and subject-matter related thereto.

2. claims: 4, 19, 27, 106-109, 138-259 (all completely), 2-3, 10-18,
20-26, 32-36, 43, 46, 47, 50, 51, 65,
71, 74, 81, 88, 93, 114,
118, 129, 133, 137 (all partially)

The peptide or polypeptide of claim 1, wherein the first hypervariable region is a CDR3 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 and 19-24, and subject-matter relating thereto.

3. claims: 44, 66, 72, 75, 89, 94-97, 113 (all completely), 2-3,
10-18, 20-26, 32-36, 43, 46, 47, 50, 51,
65, 71, 74, 81, 88, 93,
114, 118, 129, 133, 137 (all partially)

The peptide or polypeptide of claim 1, wherein the first hypervariable region is a CDR3 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-18, and subject-matter relating thereto.

4. claims: 37-42, 45, 48, 49, 52, 53 (all completely), 50, 51,
61-64, 67-70, 73, 76-87, 90-92, 98-105,
110-112, 115-118, 135, 136
(all partially)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

A peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment that (a) binds to an unknown ligand on a first cell having a first and a second state, wherein the binding is effective in the second state but is not substantially effective in the first state, and (b) by virtue of immuno-cross-reactivity, binds specifically or selectively to a ligand on a second cell, and wherein the Fv is a scFv or a dsFv and wherein the Fv optionally has one or more tags, and subject-matter related thereto.

5. claims: 54-60, 119-125 (all completely)

A method for identifying a targeting molecule and a method of production of a targeting agent, respectively, and subject-matter related thereto.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)
X	HOOGENBOOM H R ET AL: "Antibody phage display technology and its applications" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 1-20, XP004127382 ISSN: 1380-2933 * the whole document * -----	1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136	C07H21/04 C07K5/00 A61K39/395 C12N15/00 G01N33/53
X	WO 97/02479 A (UNIV YALE ; CAI XIAOHONG (US); GAREN ALAN (US)) 23 January 1997 (1997-01-23) * the whole document * ----- -/--	1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136	TECHNICAL FIELDS SEARCHED (Int.CI.7) C07K A61K
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 1 October 2004	Examiner Morawetz, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

7
EPO FORM 1503 03.82 (P04C04)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)
X	<p>HOOGENBOOM H R: "Designing and optimizing library selection strategies for generating high-affinity antibodies" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 62-70, XP004034115 ISSN: 0167-7799</p> <p>* the whole document *</p> <p>-----</p>	<p>1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136</p>	
X	<p>DE KRUIF J ET AL: "New perspectives on recombinant human antibodies" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 17, no. 10, 1 October 1996 (1996-10-01), pages 453-455, XP004034704 ISSN: 0167-5699</p> <p>* the whole document *</p> <p>-----</p> <p style="text-align: center;">-/--</p>	<p>1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136</p>	
<p>The supplementary search report has been based on the last set of claims valid and available at the start of the search.</p>			
Place of search		Date of completion of the search	Examiner
Munich		1 October 2004	Morawetz, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>..... & : member of the same patent family, corresponding document</p>			

7
EPO FORM 1503 03.82 (P04C04)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	<p>DE KRUIF J ET AL: "Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 9, 25 April 1995 (1995-04-25), pages 3938-3942, XP002149535 ISSN: 0027-8424</p> <p>* the whole document *</p> <p>-----</p>	<p>1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136</p>	
X	<p>NISSIM A ET AL: "ANTIBODY FRAGMENTS FROM A 'SINGLE POT' PHAGE DISPLAY LIBRARY AS IMMUNOCHEMICAL REAGENTS" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 3, 1994, pages 692-698, XP002926488 ISSN: 0261-4189</p> <p>* the whole document *</p> <p>-----</p> <p style="text-align: center;">-/--</p>	<p>1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136</p>	
<p>The supplementary search report has been based on the last set of claims valid and available at the start of the search.</p>			
Place of search		Date of completion of the search	Examiner
Munich		1 October 2004	Morawetz, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

7
EPO FORM 1503 03.02 (P04C04)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	ADAMS G P ET AL: "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu" BRITISH JOURNAL OF CANCER, vol. 77, no. 9, May 1998 (1998-05), pages 1405-1412, XP009037431 ISSN: 0007-0920 * the whole document * -----	1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	HUDSON P J ET AL: "High avidity scFv multimers; diabodies and triabodies" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 177-189, XP004186084 ISSN: 0022-1759 * the whole document * -----	1,5-9, 28-31, 50,51, 61-64, 67-70, 73, 76-87, 90-92, 98-105, 110-112, 115-118, 126-128, 130-132, 134-136	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 1 October 2004	Examiner Morawetz, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

7
EPO FORM 1503 03.02 (P04C04)

专利名称(译)	用于选择性癌症治疗的特定人抗体		
公开(公告)号	EP1353937A4	公开(公告)日	2005-04-13
申请号	EP2001994329	申请日	2001-12-31
[标]申请(专利权)人(译)	生物技术通用公司		
申请(专利权)人(译)	生物科技总公司		
当前申请(专利权)人(译)	生物科技总公司		
[标]发明人	HAGAI YOCHED LAZAROVITS JANETTE GUY RACHEL LIPSCHITZ ORLY SZANTON ESTHER LEVANON AVIGDOR PLAKSIN DANIEL PERETZ TUVIA		
发明人	HAGAI, YOCHED LAZAROVITS, JANETTE GUY, RACHEL LIPSCHITZ, ORLY SZANTON, ESTHER LEVANON, AVIGDOR PLAKSIN, DANIEL PERETZ, TUVIA		
IPC分类号	C12N15/09 A61K38/00 A61K38/02 A61K39/395 A61K51/00 A61P35/00 C07K14/47 C07K16/18 C12N15/13 C12P21/02 C12P21/08 C12Q1/02 C12Q1/68 C07H21/04 C07K5/00 C12N15/00 G01N33 /53		
CPC分类号	C07K14/472 A61K38/00		
优先权	09/751181 2000-12-29 US		
其他公开文献	EP1353937A2		
外部链接	Espacenet		

摘要(译)

本发明涉及肽或多肽，其包含Fv分子，其构建体，或其片段或具有增强的结合特征的片段的构建体，以选择性地和/或特异性地结合靶细胞，有利于其他细胞，其中结合选择性或特异性主要由第一高变区决定，并且其中Fv是scFv或dsFv，并且任选地具有一个或多个标签。增强的结合针对包含细胞的靶标上或靶标中的基本上暴露的和/或过表达的结合位点，所述细胞有利于结合位点基本上不可获得和/或表达的其他细胞。本发明还涉及从噬菌体展示文库中分离这些肽和多肽的方法以及编码它们的核酸分子。本发明提供了包含肽或多肽的药物组合物和用于诊断和治疗疾病，特别是癌症，最特别是急性髓性白血病的试剂盒。